About irinotecan 40 mg
Irinotecan 40 mg injection, a hot-selling oncology therapy, is now available at a reduced price. Recognized for its unrivaled efficacy as a topoisomerase I inhibitor, this in-demand solution is pivotal in the treatment of advanced and metastatic colorectal carcinoma. Each glass vial contains 40 mg of irinotecan hydrochloride trihydrate in a clear, pale yellow, odorless solution-sterile, preservative-free, and ready-to-use. Complying with USP/EP standards, it is administered via IV infusion after dilution with sodium chloride or dextrose. Its incomparable clinical reliability makes it the drug of choice for clinicians across India and export markets.
Key Advantages and Clinical Applications of Irinotecan 40 mg
Irinotecan 40 mg offers distinct advantages, including compliance with international pharmacopeia and a ready-to-use formulation. Its primary application is in intravenous treatment under medical supervision for colorectal cancer, especially in advanced or metastatic stages. The product stands out for its pivotal role in comprehensive cancer therapy, consistent potency, and convenience of use in hospital, oncology clinics, and institutional settings. Its enhanced safety profile and sterile packaging further augment its competitive edge for healthcare professionals.
Supply Ability and Market Reach for Irinotecan 40 mg
This product is distributed, exported, and traded both domestically and across export markets. With a robust supply ability tailored to meet urgent oncology requirements, vials are shipped and delivered on promptly scheduled timelines. Orders are efficiently processed, ensuring quick handover to partners nationwide as well as priority export handoffs. Reliable supply chains and strategic distribution guarantee wide market coverage within India and beyond, fulfilling the needs of the pivotal healthcare sector.
FAQ's of irinotecan 40 mg:
Q: How should Irinotecan 40 mg be prepared and administered?
A: Irinotecan 40 mg should be diluted with 0.9% sodium chloride or 5% dextrose before intravenous infusion. It must not be mixed with glucose-containing solutions and should only be administered under medical supervision.
Q: What are the key prescription requirements for Irinotecan 40 mg?
A: This medication is available by prescription only and should be prescribed by an oncologist or qualified healthcare professional, ensuring proper medical oversight and dosage adherence.
Q: When is Irinotecan 40 mg used in the clinical setting?
A: Irinotecan 40 mg is primarily indicated for the treatment of advanced or metastatic colorectal carcinoma, usually within hospital, oncology center, or clinical settings.
Q: Where can Irinotecan 40 mg be stored and for how long?
A: Store the vials below 25C, protected from light. Do not freeze. The shelf life is 24 months from the date of manufacture.
Q: What are the main competitive benefits of Irinotecan 40 mg?
A: This product offers USP/EP compliance, a sterile preservative-free formula, ready-to-use convenience, and reliable efficacy, making it a preferred choice for clinicians treating colorectal cancer.
Q: How quickly can Irinotecan 40 mg be shipped to domestic and export markets?
A: With efficient logistics, shipments are typically processed and handed over promptly for both domestic and export markets, ensuring timely delivery to hospitals and clinics.